Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Annovis Bio Inc (ANVS)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$0.67-44.72%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ANVS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations remains near negative $9 million | The company aims to control cash burn around negative $9 million in the same quarter. | Under Pressure | cash burn worsens beyond negative $9 million next quarter | Cash from operations: $-21.914M FY2026-Q2; GAAP. Published target: >= -$9 million cash from operations next quarter. The stored target says 2026-Q3; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-21,913,620 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-stage biotechnology business, not an established earnings compounder. The multi-year thesis is in a watch state: buntanetap trials have reached enrollment milestones, but financial performance is weak and the overall risk is high.
The evidence does not provide a valuation measure or clear market expectations, so whether ANVS is cheap or expensive versus peers cannot be assessed. The available signals point to uncertainty rather than a well-supported expectations gap, including a May earnings miss, an August earnings beat, and a delisting-related notice on October 30.
Near term, ANVS is likely to remain loss-making as it advances clinical studies; the latest reported quarter had an operating loss of about $14.4 million, and cash was $18.7 million at June 30. The pivotal Alzheimer’s study was fully enrolled with 850 patients, while the Parkinson’s extension had enrolled 266, but disclosures do not show a specific cash-burn target or progress against one. Near-term execution risk is elevated, including a stated concern about a possible guidance cut and a high estimated risk of an earnings miss.
The multi-year thesis hinges on clinical development progress and whether the company can manage losses and funding needs. A guidance cut or worsening economic conditions would add pressure, while continued strength among major healthcare companies could support the sector backdrop. The significance and outcome of the October 30 delisting-related notice are not detailed in the evidence.
Over the next one to three years, ANVS remains a high-risk development story with measurable trial-enrollment progress but weak financial performance and unresolved funding and regulatory concerns. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 1 of 2 supplied quarters. Management reported: “Annovis had 42.6 million shares of common stock outstanding as of June 30, 2026.” “It accepts participants who were in prior Annovis’ clinical trials as well as new patients who have deep brain stimulation (DBS).”
Delivery assessment Nov 5, 2026Advancement of clinical trials and therapeutic candidates | Progress in clinical trials could drive future growth. | Improving | clinical development stalls or regresses over next 12 months | Qualitative progress: NDA prep & March 2027 readout vs 12-month target Weave Bio partnership for NDA and March 2027 Alzheimer's readout target confirm clinical program advancement. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Operating losses remain near negative $18 million | Annovis Bio focuses on managing operating losses near negative $18 million in 2026-Q1. | Broken | operating losses worsen beyond negative $18 million next quarter | Operating income: $-14.378M FY2026-Q2; GAAP. Published target: >= -$18 million operating loss next quarter. The stored target says 2026-Q3; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-14,377,712 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “Annovis had 42.6 million shares of common stock outstanding as of June 30, 2026.” “It accepts participants who were in prior Annovis’ clinical trials as well as new patients who have deep brain stimulation (DBS).” Delivery assessment Nov 5, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.24 → $-0.97 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.24 | $16,689,000 | 1 / 2 |
| 2026-07-25 | $-1.24 | $16,689,000 | 1 / 2 |
| 2026-07-26 | $-1.24 | $16,689,000 | 1 / 2 |
| 2026-07-27 | $-1.24 | $16,689,000 | 1 / 2 |
| 2026-07-28 | $-0.89 | $0 | 2 / 3 |
| 2026-07-29 | $-0.89 | $0 | 2 / 3 |
| 2026-07-30 | $-0.89 | $0 | 2 / 3 |
| 2026-07-31 | $-0.89 | $0 | 2 / 3 |
| 2026-08-01 | $-0.89 | $0 | 2 / 3 |
| 2026-08-02 | $-0.89 | $0 | 2 / 3 |
| 2026-08-03 | $-0.89 | $0 | 2 / 3 |
| 2026-08-04 | $-0.89 | $0 | 2 / 3 |
| 2026-08-05 | $-0.89 | $0 | 2 / 3 |
| 2026-08-06 | $-0.89 | $0 | 2 / 3 |
| 2026-08-07 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-08 | $-0.89 | $0 | 2 / 3 |
| 2026-08-09 | $-0.89 | $0 | 2 / 3 |
| 2026-08-10 | $-0.89 | $0 | 2 / 3 |
| 2026-08-11 | $-0.89 | $0 | 2 / 3 |
| 2026-08-12 | $-0.89 | $0 | 2 / 3 |
| 2026-08-13 | $-0.89 | $0 | 2 / 3 |
| 2026-08-14 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-15 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-16 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-17 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-18 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-19 | $-1.24 | $16,689,000 | 2 / 3 |
| 2026-08-20 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-21 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-22 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-23 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-24 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-25 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-26 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-27 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-28 | $-0.99 | $16,689,000 | 2 / 3 |
| 2026-08-29 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-08-30 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-08-31 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-01 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-02 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-03 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-04 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-05 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-06 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-07 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-08 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-09 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-10 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-11 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-12 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-13 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-14 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-15 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-16 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-17 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-18 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-19 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-20 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-21 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-22 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-23 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-24 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-25 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-26 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-27 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-28 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-29 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-09-30 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-01 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-02 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-03 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-04 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-05 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-06 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-07 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-08 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-09 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-10 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-11 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-12 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-13 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-14 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-15 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-16 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-17 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-18 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-19 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-20 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-21 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-22 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-23 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-24 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-25 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-26 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-27 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-28 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-29 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-30 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-10-31 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-11-01 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-11-02 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-11-03 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-11-04 | $-0.97 | $16,689,000 | 2 / 3 |
| 2026-11-05 | $-0.97 | $16,689,000 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.